Skip to Content

Exact Sciences Corp EXAS

Morningstar Rating
$49.49 +0.13 (0.26%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Exact Sciences' Cancer Screening Foothold Is Strong, but Liquid Biopsy Pipeline Not Derisked Yet

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype Dx, its tissue-based genomic profiling platform with widespread use in breast cancer. It has a promising pipeline in the nascent liquid biopsy market, including a tissue-informed molecular residual disease, or MRD, test, a blood-based CRC screening test, and a multicancer early detection, or MCED, test.

Price vs Fair Value

EXAS is trading at a 586% premium.
Price
$49.37
Fair Value
$16.00
Uncertainty
Very High
1-Star Price
$311.70
5-Star Price
$18.00
Economic Moat
Gtvww
Capital Allocation
Pxlsszdzw

Bulls Say, Bears Say

Bulls

Cologuard’s staying power is underappreciated. It could take years for liquid biopsy to steal share, and Cologuard’s market share could soar past 10%.

Bears

Exact has yet to reach profitability, and the market is giving the company credit for significant future success despite historical lack of profitability.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EXAS is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$49.36
Day Range
$48.6649.95
52-Week Range
$40.66100.75
Bid/Ask
$49.43 / $49.52
Market Cap
$9.13 Bil
Volume/Avg
720,158 / 3.0 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
3.53
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Small Growth
Total Number of Employees
6,600

Competitors

Valuation

Metric
EXAS
ILMN
MYGN
Price/Earnings (Normalized)
136.24
Price/Book Value
2.903.323.23
Price/Sales
3.534.222.97
Price/Cash Flow
54.6040.71
Price/Earnings
EXAS
ILMN
MYGN

Financial Strength

Metric
EXAS
ILMN
MYGN
Quick Ratio
1.301.181.52
Current Ratio
1.641.751.99
Interest Coverage
−7.24−15.22−81.03
Quick Ratio
EXAS
ILMN
MYGN

Profitability

Metric
EXAS
ILMN
MYGN
Return on Assets (Normalized)
−0.76%1.28%−0.45%
Return on Equity (Normalized)
−1.56%2.25%−0.68%
Return on Invested Capital (Normalized)
−0.45%1.78%−0.50%
Return on Assets
EXAS
ILMN
MYGN
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
KsqvbftvrKzgz$211.9 Bil
Danaher Corp
DHR
YddgpfbngBmzvxm$186.1 Bil
IQVIA Holdings Inc
IQV
FhtgmwyznJfckzc$42.0 Bil
IDEXX Laboratories Inc
IDXX
WzhvfgmfqRgjdsq$41.0 Bil
Agilent Technologies Inc
A
TthrgzzhBlkmx$39.0 Bil
Mettler-Toledo International Inc
MTD
JzfpnytgxKnckbf$29.4 Bil
Icon PLC
ICLR
JxkhkqkjgPvyyg$27.6 Bil
Illumina Inc
ILMN
TmkklfzDvfytk$19.1 Bil
Waters Corp
WAT
DczdbykxtqGzdpk$18.6 Bil
Labcorp Holdings Inc
LH
JlmcckyqGhcrwm$18.2 Bil

Sponsor Center